@sleepingbear84 This is annoying but the chance of an actual en band review is deminimus. Doesn't really affect their time line one way or another given the plan was to launch $LQDA on April 1st regardless.
@plainyogurt21@sleepingbear84@LionelHutz_Esq Jeffs is going to have a triumphant return at JPM this January. He’ll outline pretty conclusively there the superiority of Yutrepia. Again, there is no reason for him to deal with all the nonsense of waiting around for litigation to resolve only to introduce a similar product.
@plainyogurt21@emre3 talk to an actual doctor about $UTHR's claims on better lung delivery and they'll tell you that that is all just made up nonsense. its just propaganda that Martine has spun.
@plainyogurt21@emre3 $LQDA's Yutrepia was able to dose as high as 250 mcgs and went 3x higher than where $UTHR dared to go. Patients can stay on the product much longer as a result given the higher dosage and no side effects.
@plainyogurt21@emre3 among other things, you don't cite the fact that having naive patients will see dramatically higher side effects and that Lqda went with an all naive cohort for its trial. that's a key nuance of the trial data that your facts gloss over.
@plainyogurt21@emre3 delivering summarized talking points from their competitor $UTHR and making it sound like this is well diligence research just makes you lose a lot of credence from the get go.
@LionelHutz_Esq Why post this nonsense? He didn't do any work, just a regurgitation of $UTHR's talking points. All of the deeper lung delivery nonsense is copy and paste from castagna and martine’s canned responses over the past 18 mo. I'll post a separate response.